IGF2BP2 and non-small cell lung carcinoma: We innovatively validate that EIF4A3‐triggered circDHTKD1 upregulation facilitates NSCLC glycolysis through recruiting m6A reader IGF2BP2 to stabilize PFKL, which may provide a new direction for seeking targeted therapy plans of NSCLC.